

**24th European Hematology Association (EHA) Annual Congress
13-16 June 2019 – Amsterdam (The Netherlands)**

MYELOMA AGENDA

THURSDAY, 13th June

- **Celgene - Discovery of therapeutic synergies leveraging the immune system against multiple myeloma**
Room: Auditorium
Time: 10:15 - 11:45
Type: Satellite Symposium
Chair: Jesús San Miguel, Clinical University Navarra, Pamplona, Spain
 - The quest for synergy: combination strategies in MM – J. San Miguel
 - The journey towards deeper responses and improved outcomes in NDMM – T. Fancon
 - Mapping treatment strategies for early-relapse patients – X. Leleu
 - Guiding the immune system to address unmet needs in RRMM – N. Rage

- **Amgen - Rebooting the myeloma treatment programme**
Room: Elicium 2
Time: 12:30 - 14:00
Type: Satellite Symposium
Chair: Jesús San Miguel, Clinical University Navarra, Pamplona, Spain
 - Foreword: Steady stream and changing seas in myeloma – J. San Miguel
 - An uphill battle: Overcoming treatment resistance – K. Weisel
 - A delicate balance: Tailoring treatment for elderly patients – X. Leleu
 - Big Changes May Arise: Evolution of immunotherapies – H. Einsele

- **Sanofi Genzyme - Management of relapsed and refractory multiple myeloma with novel monoclonal antibody-based regimens: an interactive conversation with the experts**
Room: Forum Hall
Time: 14:45 - 16:15
Type: Satellite Symposium
Chair: M. Attal, Toulouse University Institute of Cancer – Oncopole, France
 - Introduction and Voting on FAQs – M. Attal
 - Available Agents and Treatment Sequencing in Relapsed/Refractory Multiple Myeloma – K. Young
 - Clinical Perspective – K. Weisel

- Novel Combinations with Pomalidomide and Dexamethasone – P. Richardson
 - Clinical Perspective & Interactive Panel Discussion – K.Weisel
 - Answering FAQs: Discussion with Faculty – All
 - Closing Remarks – M Attal
-
- **Medscape Oncology - Real world treatment of R/R myeloma: clinical trials vs clinical practice**
Room: Hall 3A
Time: 14:45 - 16:15
Type: Satellite Symposium
Chair: G. Jackson, Newcastle Hospitals NHS Foundation Trust, United Kingdom
 - Welcome and Introductions – G. Jackson
 - Clinical Trials Inform - But do not Reflect Clinical Practice – M. Boccadoro
 - Clinical Trials vs Clinical Practice: Why the Discrepancies? – A Chari
 - How can we achieve our Goals in the Real World? – panel
-
- **Medscape Oncology - Building a better foundation: targeting apoptosis to enhance outcomes in relapsed/refractory myeloma**
Room: Auditorium
Time: 17:00 - 18:30
Type: Satellite Symposium
Chair: S. Kumar, Mayo Clinic College of Medicine, Rochester, United States
 - What's important in defining therapy choices? – T. Fancon
 - New Paradigms in Myeloma: Top Down - Targeting the Cell Surface – J. San Miguel
 - New Paradigms in Myeloma: Bottom Up - Targeting Cell Survival – S. Kumar
 - Challenging today's paradigms: Where will new agents fit in practice? – G. Morgan
-
- **Oncopeptides - Challenging the treatment paradigm in multiple myeloma**
Room: Hall 3B
Time: 19:15 - 20:45
Type: Satellite Symposium
Chair: X. Leleu, CHU La Miletrie, Poitiers, France
 - Challenges in treating myeloma after 1st/2nd relapse in the year 2019 and onwards – M. Dimopoulos
 - Tolerability aspects on treating myeloma – F. Davies
 - Next generation of targeted drugs for RRMM – P. Richardson

FRIDAY, 14th JUNE

- **Resistance mechanisms to novel anti-MM agents**

Room: Hall E-106

Time:

Type: Science-in-focus

Chair: N Weinhold, University Hospital Heidelberg, Germany

- Resistance to IMiDs in MM: Is Cereblon de whole story? – E Ocio
- Inside the gearbox of proteasome inhibitor-refractory multiple myeloma – C Driessen
- Resistance to immunotherapeutic agents in multiple myeloma – T Mutis

- **Optimal sequencing in relapsed/refractory myeloma**

Room: Emerald

Time: 11:30 - 12:30

Type: Meet-the-expert

Speaker: F. Gay

- **Myeloma and other monoclonal gammopathies - Biology & Translational Research**

Room: Poster area

Time: 17:30 – 19:00

Type: Poster session

SATURDAY, 15th JUNE

- **Multiple myeloma: Novel outcome endpoints in trials and in daily practice**

Room: Hall 3A

Time: 08:30 - 09:30

Type: Scientific Working group

Chair: M. Delforge

- Is MRD the new predictor for survival? – S. Oliva
- Assessment of serial treatments in myeloma – E. Terpos
- Should PROMs be a standard part of outcome measurements? – H Ludwig

- **Multiple myeloma**

Room: Auditorium

Time: 09:45 - 11:15

Type: Educational Session

Chair: S. Zweegman

- The bone marrow niche in plasma cell disorders – I. Ghobrial
- MRD in myeloma: Prognostic and therapeutic implications (including imaging) – RG. Owen
- Front-line treatment of multiple myeloma – M. Cavo

- **Immunotherapy in relapsed/refractory multiple myeloma**

Room: Auditorium

Time: 11:30-12:45

Type: Oral Session

Chairs: A. Larocca and E. Ocio

- (S823) Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus Intravenous (IV) Daratumumab (Dara) administration In patients with relapsed Or Refractory Multiple Myeloma: Columba
- (S824) A phase 3 randomized, open-label, multicenter study of isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma (RRMM)
- (S825) Evaluation of Amg 420, an anti-BCMA bispecific t-cell engager (bite ®) immunotherapy, in r/r multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase 1 dose escalation study
- (S826) Improved efficacy and safety of a dual-target CAR-T cell therapy targeting BCMA and CD38 for relapsed/refractory multiple myeloma from a phase I study
- (S827) Clinical responses and pharmacokinetics of fully human BCMA targeting CAR-T cell therapy in relapsed/refractory multiple myeloma

- **EHA-EANM Joint Symposium: FDG PET/CT in Multiple Myeloma: a useful tool?**
Room: Hall E102
Time: 14:45 - 15:45
Type: Joint Symposium
Chair: TBD
 - The hematologist perspective – E Zamagni
 - The nuclear medicine doc perspective – C. Nanni

- **Myeloma and other monoclonal gammopathies - Clinical**
Room: Poster area
Time: 17:30 – 19:00
Type: Poster session

SUNDAY, 16th JUNE

- **Novel strategies in multiple myeloma**

Room: Auditorium

Time: 08:00 – 9:15

Type: Oral session

Chairs: S.Zweegman and F. Gay

- (S1602) Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASTC in multiple myeloma: a randomized phase 2 trial by the nordic myeloma study group
- (S1603) First clinical (phase 1b/2a) study of iberdomide (cc-220; IBER), a celmod, in combination with dexamethasone in patients with relapsed/refractory multiple myeloma
- (S1604) Effectiveness of denosumab compared to zoledronic acid in bone disease treatment of multiple myeloma (MM): a meta-analysis
- (S1605) Horizon (OP-106): updated efficacy and safety of melflufen in relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (DARA) and/or pomalidomide (POM)
- (S1606) Safety and efficacy of combination of selinexor, daratumumab, and dexamethasone (SDD) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs

- **Multiple myeloma**

Room: Auditorium

Time: 09:30 - 11:00

Type: Educational Session

Chair: S. Zweegman

- The bone marrow niche in plasma cell disorders – I. Ghobrial
- MRD in myeloma: Prognostic and therapeutic implications (including imaging) – RG. Owen
- Front-line treatment of multiple myeloma – M. Cavo